



Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia

ORIGINAL RESEARCH

ARVIN PRAMUDITA

SITI ROSIDAH

NOVI YUDIA

JEFFRI SIMATUPANG

WULAN PINGKAN SIGIT

RITA NOVARIANI

PRISCILIA MYRIARDA

BAMBANG BUDI SISWANTO

*Author affiliations can be found in the back matter of this article

]u[ubiquity press

ABSTRACT

Background: Although there have been several studies investigating prognostic factors for mortality in COVID-19, there have been lack of studies in low- and middle-income countries, including Indonesia. To date, the country has the highest mortality rate among Asian countries.

Objective: We sought to identify the prognostic factors of mortality in hospitalized patients with COVID-19 in Jakarta.

Methods: In this retrospective cohort study, we included all adult inpatients (≥ 18 years old) with confirmed COVID-19 from Koja General Hospital (North Jakarta, Indonesia) who had been hospitalized between March 20th and July 31st, 2020. Demographic, clinical, laboratory, and radiology data were extracted from the medical records and compared between survivors and non-survivors. Univariate and multivariate logistic regression analysis were used to explore the prognostic factors associated with in-hospital death.

Results: Two hundred forty-three patients were included in the study, of whom 32 died. Comorbid of hypertension (OR 3.59; 95% CI 1.12–11.48; $p = 0.031$), obesity (OR 6.34; 95% CI 1.68–23.98; $p = 0.007$), immediate need of HFNC and/or IMV (OR 64.93; 95% CI 11.08–380.61; $p < 0.001$), abnormal RDW (OR 3.68; 95% CI 1.09–12.34; $p = 0.035$), ALC $< 1,000/\mu\text{L}$ (OR 3.51; 95% CI 1.08–11.44; $p = 0.038$), D-dimer > 500 ng/mL (OR 9.36; 95% CI 1.53–57.12; $p = 0.015$) on admission, as well as chloroquine treatment (OR 3.61; 95% CI 1.09–11.99; $p = 0.036$) were associated with greater risk of overall mortality in COVID-19 patients. The likelihood of mortality increased with increasing number of prognostic factors.

Conclusion: The potential prognostic factors of hypertension, obesity, immediate need of HFNC and/or IMV, abnormal RDW, ALC $< 1,000/\mu\text{L}$, D-dimer > 500 ng/mL, and chloroquine treatment could help clinicians to identify COVID-19 patients with poor prognosis at an early stage.

CORRESPONDING AUTHOR:

Arvin Pramudita

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, ID; Koja General Hospital, Jakarta, ID

arvinpramudita@yahoo.com

KEYWORDS:

COVID-19; cardiometabolic; prognostic factors; mortality; Indonesia

TO CITE THIS ARTICLE:

Pramudita A, Rosidah S, Yudia N, Simatupang J, Sigit WP, Novariani R, Myriarda P, Siswanto BB. Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia. *Global Heart*. 2022; 17(1): 9. DOI: <https://doi.org/10.5334/gh.1019>

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, China. The first confirmed case of coronavirus disease 2019 (COVID-19) in Indonesia was reported on March 2, 2020. Soon after, the disease has spread rapidly within the country. By the end of 2020, approximately 735,000 cases had been diagnosed with 22,138 deaths in Indonesia [1].

Data from Chinese Center for Disease Control and Prevention (CCDC), including more than 72,000 people with COVID-19 from the country, showed that 81% were mild (absent or mild pneumonia), 14% were severe (hypoxia, dyspnea, >50% lung involvement within 24–48 hours), 5% were critical (shock, respiratory failure, multiorgan dysfunction), and 2.3% were fatal [2]. A number of factors associated with mortality have been identified from China, such as older age, male sex, presence of comorbidities, and abnormal lab findings (high WBC, high LDH, high procalcitonin, high D-dimer, low albumin level) [2–6].

To date, Indonesia has the highest mortality rate among Asian countries with third most confirmed cases of COVID-19 after India and Iran [1]. As part of low- and middle-income countries (LMICs), this situation represents a big challenge for Indonesia with its constrained critical care capacity to treat COVID-19 and limited financial resources [7]. Despite of that, little is known about the prognostic factors contributing to the high mortality rate in Indonesia. Understanding these factors is crucial, not only for early detection of high-risk patient in the country's hospital setting, but also to guide local authorities developing appropriate policies to avoid the collapse of the healthcare system. Hence, this study was performed to identify the prognostic factors of mortality in hospitalized patients with COVID-19 in Jakarta, the capital city of Indonesia.

METHODS

STUDY DESIGN

This retrospective cohort study was conducted in Koja General Hospital, a tertiary and one of COVID-19 referral hospital in Jakarta, Indonesia. All consecutive adult patients (age ≥ 18 years) diagnosed with COVID-19 and hospitalized between March 20th and July 31st, 2020 were enrolled. A confirmed case of COVID-19 was defined as a positive result on real-time reverse transcriptase polymerase chain reaction (RT-PCR) for the presence of SARS-CoV-2 in nasopharyngeal swab specimens [8]. Patients who were referred to other hospital or still on treatment were excluded.

DATA COLLECTION

Demographic, clinical, laboratory, and radiology data were extracted from medical records of the participants. Demographic and clinical data included age, sex, symptoms on admission (cephalgia, fever, cough, dyspnea, dysphagia, rhinorrhea, chest pain, nausea, diarrhea, dyspepsia), comorbidities (hypertension, cardiovascular disease, diabetes mellitus, chronic kidney disease, asthma, tuberculosis, and obesity), vital signs on admission (blood pressure and heart rate), immediate need of supplemental oxygen, and treatment in the hospital (antibiotics, oseltamivir, and chloroquine). Laboratory data consisted of complete blood count, blood biochemistry, C-reactive protein (CRP) and D-dimer taken on the first day of admission. Chest X-ray was also taken on the first day and interpreted by a radiologist, seeking for cardiomegaly as the only indicator that could be measured objectively. The end-point of our study was overall in-hospital mortality rate, regardless of length of stay or cause of death.

STATISTICAL ANALYSIS

For the statistical analysis, age was categorized into (1) <45 years old and (2) ≥ 45 years old, following previous similar study in Indonesia [9]. Symptoms on admission, comorbidities, vital signs on admission, cardiomegaly, and treatment options in the hospital were recorded as (1) yes or (2) no. Obesity was defined as body mass index (BMI) ≥ 25 kg/m² based on the guideline from World Health Organization for Asia-Pacific population [10]. Blood pressure (BP) on admission was categorized using the cut-off of 140/90 mmHg [11]. Immediate need of supplemental oxygen was based on clinical judgement of the physician to maintain patients'

normal peripheral oxygen saturation and was recorded as (1) immediate need of high flow nasal cannula (HFNC) and/or invasive mechanical ventilation (IMV), (2) immediate need of nasal cannula up to non-rebreather mask (NRM), or (3) no immediate need of oxygen. Statistically significant hematological values were categorized as (1) normal and (2) abnormal based on reference values used at our hospital. Categories for neutrophil-to-lymphocyte ratio (NLR) were (1) >3.13 and (2) ≤ 3.13 [12]. Categories for absolute lymphocyte count (ALC) were (1) $<1,000/\mu\text{L}$ and (2) $\geq 1,000/\mu\text{L}$ [13]. Categories for CRP were (1) >10 mg/dL and (2) ≤ 10 mg/dL [14]. Categories for D-dimer were (1) >500 mg/dL and (2) ≤ 500 mg/dL [14].

Continuous variables are expressed as means \pm standard deviation or median [range] and were compared by Student's *t*-test or the Mann-Whitney U test. Categorical variables are described as number (%) and were compared by the χ^2 test or Fisher's exact test. Univariate logistic regression analysis was performed to identify prognostic factors of mortality. Multivariate logistic regression analysis was conducted with variables that showed $p < 0.05$ in univariate analysis. In all analyses, two-tailed $p < 0.05$ was taken to indicate statistical significance. All statistical analyses were performed using SPSS software (ver. 25.0; IBM, North Castle, NY, USA).

ETHICAL STATEMENT

This study was reviewed and approved by the Ethical Committee of Koja General Hospital (04/KOME/2020). The requirement for informed consent was waived because of the retrospective study design. The final follow-up date was July 31st, 2020.

RESULTS

There were 253 hospitalized patients with confirmed COVID-19 throughout our time period. Five cases were excluded as 2 patients were transferred to other hospital by patients' preference and 3 still hospitalized as of July 31st, 2020. A total of 248 patients were enrolled, of whom 243 cases were included in the study. Five cases were excluded due to incomplete key information in their medical records (**Figure 1**).




Figure 1 Flowchart.
 COVID-19 = coronavirus disease 2019.

Baseline characteristics of all patients are summarized in **Table 1**. The patients in the death group were significantly older than the patients in the alive group (54.2 ± 14 vs. 47.1 ± 14.3 , respectively, $p = 0.009$). There was no difference in sex between both groups. The death group was significantly more likely to have comorbidities of hypertension (53.1% vs. 29.4%, respectively, $p = 0.008$), diabetes mellitus (43.8% vs. 17.1%, respectively, $p = 0.001$) and obesity (37.5% vs. 14.2%, respectively, $p = 0.001$). On admission, symptom of dyspnea (56.3% vs. 35.5%, respectively, $p = 0.025$) and radiologic findings of cardiomegaly (40.6% vs. 20.4%, respectively, $p = 0.011$) were significantly more common in the death group than the alive group. More patients in the death group also needed immediate oxygen supplementation than those in the alive group significantly ($p < 0.001$). Chloroquine was given more frequently in the death group significantly (65.6% vs. 45%, respectively, $p = 0.030$).

CHARACTERISTICS	DEATH (N = 32)	ALIVE (N = 211)	P VALUE
Age			
Mean ± SD (years)	54.2 ± 14	47.1 ± 14.3	0.009
Age ≥ 45 years (%)	81.3	57.3	0.010
Sex, male (%)	53.1	53.1	0.996
Symptoms on admission			
Cephalgia (%)	15.6	23.7	0.309
Fever (%)	56.3	46	0.278
Cough (%)	71.9	55	0.072
Dyspnea (%)	56.3	35.5	0.025
Dysphagia (%)	9.4	13.7	0.496
Rhinorrhea (%)	3.1	9.5	0.233
Chest pain (%)	6.3	3.8	0.514
Nausea (%)	21.9	31.8	0.258
Diarrhea (%)	0	6.6	0.133
Dyspepsia (%)	25	16.1	0.215
Comorbidities			
Hypertension (%)	53.1	29.4	0.008
Cardiovascular disease (%)	25	12.8	0.067
Diabetes mellitus (%)	43.8	17.1	0.001
Chronic kidney disease (%)	9.4	3.8	0.164
Asthma (%)	0	2.8	0.425
Tuberculosis (%)	9.4	5.2	0.275
Obesity (%)	37.5	14.2	0.001
Vital signs on admission			
BP ≥ 140/90 mmHg (%)	34.4	40	0.544
Heart rates > 100 beats/min (%)	43.8	31.3	0.162
Immediate need of supplemental oxygen			<0.001
HFNC and/or IMV (%)	65.6	6.2	
Nasal cannula up to NRM (%)	28.1	29.4	
Not needed (%)	6.3	64.5	
Radiologic findings			
Cardiomegaly (%)	40.6	20.4	0.011
Treatment in hospital			
Antibiotics (%)	96.9	88.2	0.137
Oseltamivir (%)	93.8	88.6	0.382
Chloroquine (%)	65.6	45	0.030

Table 1 Baseline characteristics of the study participants with COVID-19. COVID-19 = coronavirus disease 2019, SD = standard deviation, BP = blood pressure, HFNC = high-flow nasal cannula, IMV = invasive mechanical ventilation, NRM = non-rebreather mask.

Laboratory findings on hospital admission are summarized in **Table 2**. In complete blood counts, white blood cells (WBC) count (9,700 [4,460 – 28,860] vs. 8,540 [2,790 – 35,450], respectively, $p = 0.049 - 0.024$) and neutrophil-to-lymphocyte ratio (NLR) (8.66 [1.91 – 30.50] vs. 3.37 [0.31 – 47.15], respectively, $p < 0.001$) were higher in the death group than the alive group. Absolute lymphocyte count (ALC) (1,008 [242 – 7,821] vs. 1,588 [16 – 6,219], respectively, $p < 0.001$) and platelet count (230,781 ± 92,319 vs. 275,110 ± 100,158, respectively, $p = 0.019$) were significantly lower in the death group. There was also a higher percentage of abnormal red cell distribution width (RDW) in the death group (43.8% vs. 22.9%, respectively, $p = 0.021$).

VARIABLES	DEATH (N = 32)	ALIVE (N = 211)	P VALUE
Hemoglobin (g/dL, median [range])	12.5 [7.6–16.9]	13.2 [5.7–18.3]	0.118–0.059
White blood cells (/μL)			
Median [range]	9700 [4460–28860]	8540 [2790–35450]	0.049–0.024
Distribution – abnormal WBC (%)	40.6	22.7	0.030
Hematocrite (% , median [range])	36.1 [20.9–49.7]	37.9 [17–52.1]	0.145–0.072
Platelet (/μL)			
Mean ± SD	230781 ± 92319	275110 ± 100158	0.019
Distribution – abnormal PLT (%)	21.9	13.3	0.153
Red cell distribution width (%)			
Median [range]	13.8 [11.7–19.6]	13.1 [11.3–38]	0.006–0.003
Distribution – abnormal RDW (%)	43.8	22.9	0.012
Neutrophil-lymphocyte ratio			
Median [range]	8.66 [1.91–30.50]	3.37 [0.31–47.15]	<0.001
Distribution – NLR > 3.13 (%)	84.4	54	0.001
Absolute lymphocyte count (/μL)			
Median [range]	1008 [242–7821]	1588 [16–6219]	<0.001
Distribution – ALC < 1,000 (%)	50	18.5	<0.001
Random blood glucose (mg/dL)			
Median [range]	142 [63–550]	114 [64–522]	<0.001
Distribution – RBG ≥ 200 (%)	28.1	12.3	0.018
Blood urea nitrogen (mg/dL, median [range])	51.8 [13–362.6]	21.4 [3.4–184]	<0.001
Creatinine (mg/dL)			
Median [range]	1.46 [0.59–16.12]	0.87 [0.36–105]	<0.001
Distribution – Cr > 1.2 (%)	62.5	22.7	<0.001
C-reactive protein (mg/dL)			
Median [range]	11.2 [0.38–31.29]	1.90 [0–32]	<0.001
Distribution – CRP > 10 (%)	62.5	26.5	<0.001
D-dimer (ng/mL)			
Median [range]	2922 [590–10000]	987 [141–15441]	<0.001
Distribution – D-dimer > 500 (%)	93.8	46.9	<0.001
	n = 21	n = 148	
Alanine transaminase (U/L, median [range])	38 [10–480]	28.5 [4–247]	0.06–0.03
Aspartate transaminase (U/L, median [range])	55 [15–1500]	26 [12–269]	<0.001
	n = 32	n = 149	
Sodium (mEq/L, median [range])	134 [119–159]	138 [109–152]	0.005–0.002
Potassium (mEq/L, median [range])	4.16 [2.8–8]	3.63 [1.62–4.93]	<0.001
Chloride (mEq/L, median [range])	104 [88–115]	105 [90–114]	0.823–0.411

Table 2 Laboratory findings on admission in patients with COVID-19.

COVID-19 = coronavirus disease 2019, abnormal WBC = WBC < 4000 or > 11000 (/μL), abnormal PLT = PLT < 150000 or > 450000 (/μL), abnormal RDW = RDW > 14%.

With regard to blood chemistry, creatinine level was significantly higher in the death group than the alive group (1.46 [0.59 – 16.12] vs. 0.87 [0.36 – 105] mg/dL, respectively, p < 0.001). Concentrations of blood urea nitrogen and random blood glucose were also significantly higher in the death group. Not all of the patients were assessed for their liver function and electrolyte

PROGNOSTIC FACTORS	OR (95% CI)	P VALUE
Age		
≥45 years	3.22 (1.27–8.16)	0.010
<45 years	Reference	
Dyspnea		
Yes	2.33 (1.10–4.95)	0.025
No	Reference	
Hypertension		
Yes	2.72 (1.28–5.79)	0.008
No	Reference	
Diabetes mellitus		
Yes	3.78 (1.72–8.29)	0.001
No	Reference	
Obesity		
Yes	3.62 (1.60–8.16)	0.001
No	Reference	
Immediate need of supplemental oxygen		
HFNC and/or IMV	109.85 (23.13–521.70)	<0.001
Nasal cannula up to NRM	9.87 (2.07–47.04)	0.004
Not needed	Reference	
Cardiomegaly		
Yes	2.67 (1.22–5.84)	0.011
No	Reference	
Abnormal WBC		
Yes	2.32 (1.07–5.05)	0.030
No	Reference	
Abnormal RDW		
Yes	2.62 (1.22–5.66)	0.012
No	Reference	
NLR		
>3.13	4.60 (1.70–12.39)	0.001
≤3.13	Reference	
ALC		
<1,000 /μL	4.41 (2.03–9.58)	<0.001
≥1,000 /μL	Reference	
D-dimer		
>500 ng/mL	16.97 (3.95–72.83)	<0.001
≤500 ng/mL	Reference	
CRP		
>10 mg/dL	4.61 (2.11–10.04)	<0.001
≤10 mg/dL	Reference	
RBG		
≥200 mg/dL	2.78 (1.16–6.67)	0.018
<200 mg/dL	Reference	
Creatinine		
>1.2 mg/dL	5.66 (2.58–12.40)	<0.001
≤1.2 mg/dL	Reference	
Treatment - Chloroquine		
Yes	2.33 (1.07–5.08)	0.030
No	Reference	

Table 3 Univariate analysis of prognostic factors for overall mortality in COVID-19.

COVID-19 = coronavirus disease 2019, OR = odds ratio, CI = confidence interval, HFNC = high-flow nasal cannula, IMV = invasive mechanical ventilation, NRM = non-rebreather mask, WBC = white blood cells, RDW = red cell distribution width, NLR = neutrophil-to-lymphocyte ratio, ALC = absolute lymphocyte count, CRP = C-reactive protein, RBG = random blood glucose.

status. From the available data (n = 169), concentrations of alanine transaminase and aspartate transaminase were significantly higher in the death group. On the other hand (n = 181), sodium level was significantly lower yet potassium level was significantly higher in the death group.

C-reactive protein, as an inflammation-related marker, was significantly higher in the death group than the alive group (11.2 [0.38 – 31.29] vs. 1.90 [0 – 32] mg/dL, respectively, p < 0.001). The same result was also applied for D-dimer (2,922 [590 – 10,000] vs. 987 [141 – 15,441] ng/mL, respectively, p < 0.001).

PROGNOSTIC FACTORS FOR MORTALITY OF COVID-19

Multivariate analysis with logistic regression model was performed using selected factors from univariate analysis (**Table 3**) and demonstrated that comorbid of hypertension (odds ratio [OR] 3.59; 95% confidence interval (CI) 1.12–11.48; p = 0.031), obesity (OR 6.34; 95% CI 1.68–23.98; p = 0.007), immediate need of HFNC and/or IMV (OR 64.93; 95% CI 11.08–380.61; p < 0.001), abnormal RDW (OR 3.68; 95% CI 1.09–12.34; p = 0.035), ALC < 1,000/ μ L (OR 3.51; 95% CI 1.08–11.44; p = 0.038), D-dimer > 500 ng/mL (OR 9.36; 95% CI 1.53–57.12; p = 0.015) on admission, as well as chloroquine treatment (OR 3.61; 95% CI 1.09–11.99; p = 0.036) were associated with greater risk of overall mortality in COVID-19 patients (**Table 4**). The likelihood of mortality increased with increasing number of prognostic factors (p < 0.001, test for trend) (**Figure 2**).

PROGNOSTIC FACTORS	OVERALL MORTALITY	
	OR (95% CI)	P VALUE
Age > 45 year	1.26 (0.30–5.28)	0.754
Dyspnea	1.58 (0.47–5.25)	0.458
Hypertension	3.59 (1.12–11.48)	0.031
Diabetes mellitus	0.69 (0.16–2.97)	0.617
Obesity	6.34 (1.68–23.98)	0.007
Oxygen – nasal cannula up to NRM	2.99 (0.54–16.42)	0.207
Oxygen – HFNC and/or IMV	64.93 (11.08–380.61)	<0.001
Cardiomegaly	1.22 (0.31–4.82)	0.781
Abnormal WBC count	1.96 (0.55–7.06)	0.301
Abnormal RDW	3.68 (1.09–12.34)	0.035
NLR > 3.13	0.48 (0.10–2.20)	0.344
ALC < 1000 / μ L	3.51 (1.08–11.44)	0.038
D-dimer > 500 ng/mL	9.36 (1.53–57.12)	0.015
CRP > 10 mg/dL	1.03 (0.30–3.56)	0.961
RBG \geq 200 mg/dL	3.24 (0.76–13.92)	0.113
Creatinine > 1.2 mg/dL	1.85 (0.56–6.16)	0.316
Treatment – Chloroquine	3.61 (1.09–11.99)	0.036

Table 4 Multivariate logistic regression analysis of prognostic factors for mortality in COVID-19. COVID-19 = coronavirus disease 2019, OR = odds ratio, CI = confidence interval, HFNC = high-flow nasal cannula, IMV = invasive mechanical ventilation, NRM = non-rebreather mask, WBC = white blood cells, RDW = red cell distribution width, NLR = neutrophil-to-lymphocyte ratio, ALC = absolute lymphocyte count, CRP = C-reactive protein, RBG = random blood glucose.

DISCUSSION

Jakarta is the capital of Indonesia and currently has the highest mortality rate and most confirmed cases of COVID-19 in the country [15]. Moreover, it is the most populous region in Indonesia. Koja General Hospital is one of the first hospitals appointed by the local government to become a COVID-19 referral center in the area. The hospital is located in a densely populated area of Koja in the North Jakarta district which has the lowest Human Development Index among the capital's main districts [16].

Among the 243 patients with COVID-19, the in-hospital case fatality rate was 13.7% in this study.




Figure 2 Overall mortality rates of COVID-19 according to the presence of prognostic factors.

COVID-19 = coronavirus disease 2019.

We showed that the presence of hypertension, obesity, immediate need of HFNC and/or IMV, abnormal RDW, ALC $< 1,000/\mu\text{L}$, D-dimer $> 500 \text{ ng/mL}$, and chloroquine treatment were independent predictors of mortality in hospitalized adult COVID-19 patients. To our knowledge, this is one of the first studies to evaluate the prognostic factors of mortality in COVID-19 in Indonesia. It is unique in examining the combinations of demographic, clinical, laboratory, and radiological characteristics and their associations with death.

Studies from multiple countries have reported evidence that underlying cardiometabolic conditions may be associated with worse prognosis of COVID-19 [2, 17–20]. Our findings supported those of previous reports from other countries, particularly hypertension and obesity, as they were associated with mortality. Diabetes was also found to be in a significantly higher proportion in our death group. However, different from other studies, it was not associated with mortality after adjustment with other prognostic factors. Cardiometabolic diseases, including hypertension, diabetes mellitus and obesity, are associated with diminished innate and adaptive immune response [21–23]. They are also linked with endothelial dysfunction and persistent low-grade inflammation [18]. Obesity reduces baseline pulmonary function and ventilatory reserve, which could predispose to worse COVID-19 outcomes [24]. The association between angiotensin-converting enzyme 2 (ACE2) expression and hypertension may also partly explain the high prevalence of severe COVID-19 in hypertensive patients [6]. Biologic plausibility is further supported by the unusual harms of COVID-19 related to vascular endothelial cells, in the lungs and throughout the body [25]. Overall, individuals with cardiometabolic conditions are likely predisposed to higher risks of lung injury, cytokine storm, and respiratory failure from COVID-19 infection [19, 24].

These conditions also promote prothrombotic milieu as the basis for coagulopathy found in COVID-19 patients [26]. Furthermore, hypoxia-mediated hyperviscosity may also aggravate thrombosis [25, 27]. Vascular injury, along with the hypercoagulability state, may aggravate the risk of cardiac injury and thus further demonstrate COVID-19 and its relationship with the heart. An increase of D-dimer level in COVID-19 patients, both at admission and during hospitalization, has been linked with increased mortality and admission to critical care [25, 28]. Our study also suggested the same finding, as D-dimer $> 500 \text{ ng/mL}$ was one of the strongest predictors of mortality among other available factors.

The significant difference in immediate need of oxygen supplementation between survivors and non-survivors in our study indicates this factor is associated with the severity of illness. Interestingly, our multivariate analysis showed only the immediate need of HFNC and/or IMV as prognostic factor for mortality. Both HFNC and IMV were used in our hospital for patients with respiratory failure. Our findings confirmed reports from previous studies that the need

for mechanical ventilation was associated with high mortality in COVID-19 patients [29–32]. Profound hypoxemia from respiratory failure enhances various cytotoxic functions of neutrophils and can promote hyperinflammation. Thus, it not only represents a consequence of respiratory disease but also contributes significantly to progressive lung damage after establishment of the initial injury [33, 34].

Our hematological findings showed higher RDW and lymphopenia as independent predictors for mortality. RDW reflects the heterogeneity in the volume of circulating erythrocytes. In critically ill patients with sepsis, baseline RDW has been shown to be a significant and independent predictor of mortality [35]. Consistent with our findings, numerous studies have reported the association of elevated RDW with mortality in the context of COVID-19 [36–38]. The exact mechanism behind the association has yet to be elucidated. Multiple theoretically viable hypotheses can be made to justify the prognostic role of RDW in COVID-19, including direct cytopathic injury due to infection of circulating erythrocytes, indirect erythrocyte damage consequent to intravascular coagulopathy, dysfunctional hematopoiesis due to hyperinflammatory state, and profound disturbance of iron metabolism due to the sustained inflammatory response [36, 39].

Lymphopenia is the most common abnormality on the complete blood count in COVID-19 patients [14, 25]. Low lymphocytes are also associated with poor prognosis, with lymphocyte percentage <10% on the WBC differential is strongly associated with decreased survival [40]. A recent meta-analysis proposed that lymphopenia is an important hematological signal of severe COVID-19 and could be a practical parameter to predict severe outcomes [41]. Numerous possible explanations for lymphopenia in COVID-19 have been proposed, including destruction of lymphocytes via angiotensin-converting enzyme 2 (ACE2) receptor, lymphatic organ damage, acidemia, bone marrow suppression, and cytokine storm [28, 40, 42].

Chloroquine is an anti-malarial 4-aminoquinoline shown to have in vitro activity against SARS-CoV-2 and may have beneficial immunomodulatory effects in vivo [43–44]. An initial report from Gao et al. described the superiority of chloroquine for the treatment of COVID-19-associated pneumonia, compared to the control treatment, in 100 patients enrolled from 10 hospitals in China [45]. Further related study was not available yet. On the other hand, hydroxychloroquine was preferable in other studies due to its overall efficacy and safety. Still, data from previous observational studies were still inconsistent. Two large retrospective observational studies of hospitalized patients with COVID-19 reported no significant reduction in risk of in-hospital mortality for those who received hydroxychloroquine when compared to control [46–47]. Conversely, another large retrospective cohort study reported a survival benefit among hospitalized patients who received hydroxychloroquine compared to those who did not [48]. However, a substantially higher percentage of patients in the hydroxychloroquine arms also received corticosteroids (77.1% of patients in the hydroxychloroquine arms vs. 36.5% of patients in the control arm). This imbalance in corticosteroid use may confounded the findings as steroids were reported to improve the survival rate of patient with COVID-19 in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial [49].

Our study found that the use of chloroquine was associated with in-hospital death of hospitalized COVID-19 patients. The drug was given in the form of generic chloroquine phosphate (a 250-mg tablet containing a 150-mg base equivalent) two tablets every 12 hours for 5 consecutive days. No corticosteroid was given to our patients. Several studies have reported their concerns regarding the adverse effect of this 4-aminoquinoline drug, most notably cardiovascular toxicity, i.e., QT prolongation with an increased risk of cardiac complications in an already vulnerable population [47, 50]. In RECOVERY trial, the patients who received hydroxychloroquine had a longer median hospital stay and, among those who were not on invasive mechanical ventilation at the time of randomization, a higher risk of invasive mechanical ventilation or death than those who received the standard of care [51]. In another randomized controlled trial (RCT) among hospitalized patients with mild to moderate COVID-19 in Brazil, more adverse events occurred among patients who received hydroxychloroquine among those who received the standard of care [52]. An RCT of hospitalized patient with severe COVID-19 was discontinued early when preliminary results showed higher rates of mortality and QT prolongation in association with higher dose of chloroquine treatment [53].

The strength of this study is that even though this study only includes one hospital in Jakarta, Koja General Hospital is also one of the capital city referral hospital. Therefore, there are many COVID-19 patients hospitalized with different demographics that represent general population.

However, in the first few months of COVID-19 pandemic in Indonesia, some patients died in the hospital with inconclusive PCR results due to the overwhelmed diagnostic facility, thus their role might be underestimated in predicting in-hospital death. A national-scale cohort study should be done to address this limitation and to obtain validation of the prognostic factors.

In conclusion, we identified seven independent predictors of mortality in hospitalized adult COVID-19 patients in Jakarta: hypertension, obesity, immediate need of HFNC and/or IMV, abnormal RDW, ALC < 1,000/ μ L, D-dimer > 500 ng/mL, and chloroquine treatment were independent predictors of mortality in hospitalized adult COVID-19 patients. The likelihood of mortality increased with increasing number of prognostic factors. These findings could provide valuable insight for Indonesia and other LMICs to establish effective strategies for detecting high-risk patients as early as possible and distributing healthcare resources effectively.

DATA ACCESSIBILITY STATEMENT

Datasets of clinical and laboratory data presented in the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGEMENTS

We thank everyone involved in the COVID-19 management and treatment team from Koja General Hospital, Jakarta, Indonesia. Particularly, we thank Adam Fathony, MD; Adhy Nalagiri Silavatto, MD; Cleine Michaela, MD; Edi Setiawan, MD; Eric Hermansyah, MD; Eufрата Silvestris Junus, MD; Hendra Dwi Kurniawan, MD; Indry Putri Festari, MD; Irfan Ferdinand, MD; Luly Nur El Wally, MD; Mochamad Okyana Bagja Suwala, MD; Natasja Rosa Munde, MD; Rahmat Hidayat, MD; Riyanda Akbar, MD; Samuel Panjaitan, MD; Sandy, MD; Sora Kerova, MD; and Sri Feliciani, MD for supporting the data collection, and Nurfanida Librianty, MD for the interpretation of chest X-ray. We also thank Jessica Marsigit, MD for the scientific advice.

COMPETING INTERESTS

The authors have no competing interest to declare.

AUTHOR CONTRIBUTIONS

BBS, AP, SR, RN, and PM contributed equally to study conception and design. AP, SR, NY, JS, and WPS contributed to data collection and drafting of the manuscript. AP, RN, PM, and BBS contributed to data analysis and data interpretation. RN, PM, and BBS revised the final manuscript. All authors have read and approved the manuscript.

AUTHOR AFFILIATIONS

Arvin Pramudita  orcid.org/0000-0001-6383-625X

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, ID; Koja General Hospital, Jakarta, ID

Siti Rosidah  orcid.org/0000-0003-3118-3017

Koja General Hospital, Jakarta, ID

Novi Yudia  orcid.org/0000-0002-4296-548X

Koja General Hospital, Jakarta, ID

Jeffri Simatupang  orcid.org/0000-0003-4410-5376

Koja General Hospital, Jakarta, ID

Wulan Pingkan Sigit  orcid.org/0000-0001-6264-4547

Koja General Hospital, Jakarta, ID

Rita Novariani  orcid.org/0000-0001-6246-3244

Koja General Hospital, Jakarta, ID

Priscilia Myriarda  orcid.org/0000-0001-7872-5982

Koja General Hospital, Jakarta, ID

Bambang Budi Siswanto  orcid.org/0000-0003-3998-1590

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, ID

1. **Dong E, Du H, Gardner L.** An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020; 20(5): 533–4. DOI: [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
2. **Wu Z, McGoogan JM.** Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020; 323(13): 1239–42. DOI: <https://doi.org/10.1001/jama.2020.2648>
3. **Zhou F, Yu T, Du R,** et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet.* 2020; 395(10229): 1054–62. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
4. **Chen TL, Dai Z, Mo P,** et al. Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study. *J Gerontol A Biol Sci Med Sci.* 2020; 75(9): 1788–95. DOI: <https://doi.org/10.1093/gerona/glaa089>
5. **Zhang J, Wang X, Jia X,** et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect.* 2020; 26(6): 767–72. DOI: <https://doi.org/10.1016/j.cmi.2020.04.012>
6. **Li X, Xu S, Yu M,** et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020; 146(1): 110–8. DOI: <https://doi.org/10.1016/j.jaci.2020.04.006>
7. **Phua J, Faruq MO, Kulkarni AP,** et al. Critical care bed capacity in Asian countries and regions. *Crit Care Med.* 2020; 48(5): 654–62. DOI: <https://doi.org/10.1097/CCM.0000000000004222>
8. **Sethuraman N, Jeremiah SS, Ryo A.** Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA – J Am Med Assoc.* 2020; 323(22): 2249–51. DOI: <https://doi.org/10.1001/jama.2020.8259>
9. **Burhan E, Syam AF, Rahyussalim AJ,** et al. The emergence of COVID-19 in Indonesia: Analysis of predictors of infection and mortality using independent and clustered data approaches. *medRxiv;* 2020. DOI: <https://doi.org/10.1101/2020.07.10.20147942>
10. **WHO/IASO/IOTF.** *The Asia-Pacific perspective: Redefining obesity and its treatment.* Melbourne: Health Communications Australia; 2000.
11. **Chobanian AV, Bakris GL, Black HR,** et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *JAMA.* 2003; 289: 2560–72. DOI: <https://doi.org/10.1001/jama.289.19.2560>
12. **Liu J, Liu Y, Xiang P,** et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. *J Transl Med.* 2020; 18(1): 1–12. DOI: <https://doi.org/10.1186/s12967-020-02374-0>
13. **Wagner J, DuPont A, Larson S, Cash B, Farooq A.** Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. *Int J Lab Hematol.* 2020; 42(6): 761–5. DOI: <https://doi.org/10.1111/ijlh.13288>
14. **Guan W, Ni Z, Hu Y,** et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020; 382(18): 1708–20. DOI: <https://doi.org/10.1056/NEJMoa2002032>
15. **World Health Organization Indonesia.** Coronavirus Disease 2019 (COVID-19) Situation Report 43 [Internet]. 2021. Retrieved from: https://cdn.who.int/media/docs/default-source/searo/indonesia/covid19/external-situation-report-43_17-february.pdf?sfvrsn=1889cdf9_5 (accessed 23 February 2021).
16. **Widarta S.** (ed.) *Indeks Pembangunan Manusia DKI Jakarta 2020.* Jakarta: Badan Pusat Statistik Provinsi DKI Jakarta; 2020.
17. **Richardson S, Hirsch JS, Narasimhan M,** et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *JAMA – J Am Med Assoc.* 2020; 323(20): 2052–9. DOI: <https://doi.org/10.1001/jama.2020.6775>
18. **Svensson P, Hofmann R, Häbel H, Jernberg T, Nordberg P.** Association between cardiometabolic disease and severe COVID-19: A nationwide case-control study of patients requiring invasive mechanical ventilation. *BMJ Open.* 2021; 11(2): 1–10. DOI: <https://doi.org/10.1136/bmjopen-2020-044486>
19. **O’hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D.** Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the united states: A comparative risk assessment analysis. *J Am Heart Assoc.* 2021; 10(5): 1–27. DOI: <https://doi.org/10.1161/JAHA.120.019259>
20. **De Almeida-Pititto B, Dualib PM, Zajdenverg L,** et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. *Diabetol Metab Syndr [Internet].* 2020; 12(1): 1–12. DOI: <https://doi.org/10.1186/s13098-020-00586-4>
21. **Geerlings SE, Hoepelman AIM.** Immune dysfunction in patients with diabetes mellitus (DM). *FEMS Immunol Med Microbiol.* 1999; 26(3–4): 259–65. DOI: <https://doi.org/10.1111/j.1574-695X.1999.tb01397.x>
22. **Andersen CJ, Murphy KE, Fernandez ML.** Impact of obesity and metabolic syndrome on immunity. *Adv Nutr.* 2016; 7(1): 66–75. DOI: <https://doi.org/10.3945/an.115.010207>

23. **Singh MV, Chapple MW, Harwani SC, Abboud FM.** The immune system and hypertension. *Immunol Res.* 2014; 59(1–3): 243–53. DOI: <https://doi.org/10.1007/s12026-014-8548-6>
24. **Sharifi Y, Payab M, Mohammadi-Vajari E,** et al. Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: A review. *J Diabetes Metab Disord.* 2021; (0123456789). DOI: <https://doi.org/10.1007/s40200-021-00822-2>
25. **Gupta A, Madhavan MV, Sehgal K,** et al. Extrapulmonary manifestations of COVID-19. *Nat Med.* 2020; 26(7): 1017–32. DOI: <https://doi.org/10.1038/s41591-020-0968-3>
26. **Lillicrap D.** Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. *J Thromb Haemost.* 2020; 18(4): 786–7. DOI: <https://doi.org/10.1111/jth.14781>
27. **Paz LO, Capodanno D, Montalescot G, Angiolillo DJ.** Coronavirus Disease 2019 – associated thrombosis and coagulopathy: Review of the pathophysiological characteristics and implications for antithrombotic management. *J Am Hear Assoc.* 2021; 10: e019650. DOI: <https://doi.org/10.1161/JAHA.120.019650>
28. **Terpos E, Ntanasis-Stathopoulos I, Elalamy I,** et al. Hematological findings and complications of COVID-19. *Am J Hematol.* 2020; 95(7): 834–47. DOI: <https://doi.org/10.1002/ajh.25829>
29. **Bonnet N, Martin O, Boubaya M,** et al. High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: A retrospective study. *Ann Intensive Care.* 2021; 11(1): 1–9. DOI: <https://doi.org/10.1186/s13613-021-00825-5>
30. **King CS, Sahjwani D, Brown AW,** et al. Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. *PLoS One.* 11 November 2020; 15: 1–9. DOI: <https://doi.org/10.1371/journal.pone.0242651>
31. **Bahl A, Van Baalen MN, Ortiz L,** et al. Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. *Intern Emerg Med.* 2020; 15(8): 1485–99. DOI: <https://doi.org/10.1007/s11739-020-02509-7>
32. **Oliveira E, Parikh A, Lopez-Ruiz A,** et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS One.* 3 March 2021; 16: 1–14. DOI: <https://doi.org/10.1371/journal.pone.0249038>
33. **Eltzschig HK, Carmeliet P.** Hypoxia and inflammation. *N Engl J Med.* 2011; 364(7): 656–65. DOI: <https://doi.org/10.1056/NEJMra0910283>
34. **Mejía F, Medina C, Cornejo E,** et al. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. *PLoS One.* 2020; 15(12): 1–12. DOI: <https://doi.org/10.1371/journal.pone.0244171>
35. **Zhang L, Yu CH, Guo KP, Huang CZ, Mo LY.** Prognostic role of red blood cell distribution width in patients with sepsis: A systematic review and meta-analysis. *BMC Immunol.* 2020; 21(1): 1–8. DOI: <https://doi.org/10.1186/s12865-020-00369-6>
36. **Foy BH, Carlson JCT, Reinertsen E,** et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. *JAMA Netw Open.* 2020; 3(9): 1–13. DOI: <https://doi.org/10.1001/jamanetworkopen.2020.22058>
37. **Karampitsakos T, Akinosoglou K, Papaioannou O,** et al. Increased red cell distribution width Is associated with disease severity in hospitalized adults with SARS-CoV-2 Infection: An observational multicentric study. *Front Med.* 2020 December; 7: 3–6. DOI: <https://doi.org/10.3389/fmed.2020.616292>
38. **Soni M, Gopalakrishnan R.** Significance of RDW in predicting mortality in COVID-19—An analysis of 622 cases. *Int J Lab Hematol.* 2021 March; 1–3. DOI: <https://doi.org/10.1111/ijlh.13526>
39. **Henry BM, Benoit JL, Benoit S,** et al. Red blood cell distribution width (RDW) predicts COVID-19 severity: A prospective, observational study from the Cincinnati SARS-CoV-2 Emergency Department cohort. *Diagnostics.* 2020; 10(9): 1–9. DOI: <https://doi.org/10.3390/diagnostics10090618>
40. **Tan L, Wang Q, Zhang D,** et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther.* 2020; 5: 33. DOI: <https://doi.org/10.1038/s41392-020-0148-4>
41. **Zhao Q, Meng M, Kumar R, Wu Y, Huang J.** Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. *Int J Infect Dis.* 2020; 96: 131–5. DOI: <https://doi.org/10.1016/j.ijid.2020.04.086>
42. **Fathi N, Rezaei N.** Lymphopenia in COVID-19: Therapeutic opportunities. *Cell Biol Int.* 2020; 44(9): 1792–7. DOI: <https://doi.org/10.1002/cbin.11403>
43. **Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.** Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA – J Am Med Assoc.* 2020; 323(18): 1824–36. DOI: <https://doi.org/10.1001/jama.2020.6019>
44. **Wang M, Cao R, Zhang L,** et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020; 30(3): 269–71. DOI: <https://doi.org/10.1038/s41422-020-0282-0>
45. **Gao J, Tian Z, Yang X.** Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends.* 2020; 14(1): 1–2. DOI: <https://doi.org/10.5582/bst.2020.01047>

46. **Geleris J, Sun Y, Platt J**, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020; 382(25): 2411–8. DOI: <https://doi.org/10.1056/NEJMoa2012410>
47. **Rosenberg ES, Dufort EM, Udo T**, et al. Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State. *JAMA – J Am Med Assoc*. 2020; 323(24): 2493–502. DOI: <https://doi.org/10.1001/jama.2020.8630>
48. **Arshad S, Kilgore P, Chaudhry ZS**, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis*. 2020; 97: 396–403. DOI: <https://doi.org/10.1016/j.ijid.2020.06.099>
49. **The RECOVERY Collaborative Group**. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *N Engl J Med*. 2020; 1–11.
50. **Mahévas M, Tran VT, Roumier M**, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data. *BMJ*. 2020; 369: m1884.
51. **The RECOVERY Collaborative Group**. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020; 383(21): 2030–40. DOI: <https://doi.org/10.1056/NEJMoa2022926>
52. **Cavalcanti AB, Zampieri FG, Rosa RG**, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020; 383(21): 2041–52. DOI: <https://doi.org/10.1056/NEJMoa2019014>
53. **Borba MGS, Val FFA, Sampaio VS**, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open*. 2020; 3(4.23): e208857. DOI: <https://doi.org/10.1001/jamanetworkopen.2020.8857>

TO CITE THIS ARTICLE:

Pramudita A, Rosidah S, Yudia N, Simatupang J, Sigit WP, Novariani R, Myriarda P, Siswanto BB. Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia. *Global Heart*. 2022; 17(1): 9. DOI: <https://doi.org/10.5334/gh.1019>

Submitted: 28 February 2021

Accepted: 24 January 2022

Published: 18 February 2022

COPYRIGHT:

© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.

Global Heart is a peer-reviewed open access journal published by Ubiquity Press.